EQS-Adhoc: LifeWatch AG: BioTelemetry gibt Erhöhung des Angebotspreises für das öffentliche Übernahmeangebot für LifeWatch bekannt
- Lesezeichen für Artikel anlegen
- Artikel Url in die Zwischenablage kopieren
- Artikel per Mail weiterleiten
- Artikel auf X teilen
- Artikel auf WhatsApp teilen
- Ausdrucken oder als PDF speichern
Erwähnte Instrumente
- LifeWatch AGAktueller Kursstand:VerkaufenKaufen
EQS Group-Ad-hoc: LifeWatch AG / Schlagwort(e): Übernahmeangebot LifeWatch AG: BioTelemetry gibt Erhöhung des Angebotspreises für das öffentliche Übernahmeangebot für LifeWatch bekannt 24.05.2017 / 07:00 CET/CEST Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR BioTelemetry, Inc. gibt Erhöhung des Angebotspreises für das öffentliche Übernahmeangebot für LifeWatch AG bekannt ZUG/Schweiz, 24. Mai 2017 - BioTelemetry (NASDAQ: BEAT) gab gestern bekannt, den Angebotspreis für alle ausstehenden Namensaktien von LifeWatch AG zu erhöhen. Weitere Details wurden durch BioTelemetry in der Ergänzung Nr. 3 zum Angebotsprospekt publiziert. Für Rückfragen: Zu LifeWatch AG Für weitere Informationen: siehe www.lifewatch.com. E-Mail Alert: Um regelmässig die neusten Informationen zu LifeWatch zu erhalten und Unterlagen anzufordern, registrieren Sie sich bitte unter https://www.lifewatch.com/Investor-Relations/Alert-Service.html. Zu BioTelemetry Für weitere Informationen: siehe www.biotelinc.com Cautionary Statement Regarding Forward-Looking Statements OFFER RESTRICTIONS Notice to U.S. Persons Holding LifeWatch Shares According to the laws of Switzerland, LifeWatch shares tendered into the Offer may be withdrawn after they are tendered until the expiration of the main offer period. BioTelemetry and any of its subsidiaries and any advisor, broker or financial institution acting as an agent or for the account or benefit of BioTelemetry or the Offeror may, subject to applicable Swiss securities laws, rules and regulations, make certain purchases of, or arrangements to purchase, LifeWatch shares from shareholders of LifeWatch who are willing to sell their LifeWatch shares outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices. The Offeror will disclose promptly any information regarding such purchases of LifeWatch shares in Switzerland through the electronic media and/or the stock exchange and in the U.S. by means of a press release, if and to the extent required under applicable laws, rules and regulations in Switzerland. It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. federal securities laws, since LifeWatch is located in a non-U.S. jurisdiction, and some or all of its officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment. The receipt of cash and stock consideration in the Offer by a U.S. shareholder will generally be a taxable transaction for U.S. federal, state and local income tax purposes. Each U.S. shareholder is urged to consult his independent professional adviser immediately regarding the tax consequences of acceptance of the Offer. Securities may not be offered or sold in the U.S. absent registration or an exemption from registration under the U.S. Securities Act. It is expected that the Offer will be subject to a Tier I exemption pursuant to Rule 14d-1(c) of the U.S. Securities Exchange Act of 1934, as amended, and that the issuance of BioTelemetry Common Stock in connection therewith will be exempt from registration under the U.S. Securities Act of 1933, as amended, pursuant to Rule 802 thereof. Neither the Securities and Exchange Commission nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer, (b) passed upon the merits or fairness of the Offer, or (c) passed upon the adequacy or accuracy of the disclosure in the pre-announcement. Any representation to the contrary is a criminal offense in the U.S. Im Zweifelsfall gilt die englische Originalmeldung. Ende der Ad-hoc-Mitteilung |
Sprache: | Deutsch |
Unternehmen: | LifeWatch AG |
Baarerstrasse 139 | |
6300 Zug | |
Schweiz | |
Telefon: | +41 41 728 67 78 |
Internet: | www.lifewatch.com |
ISIN: | CH0012815459 |
Valorennummer: | 811189 |
Börsen: | Freiverkehr in Berlin, Stuttgart; Open Market in Frankfurt; SIX Swiss Exchange |
Ende der Mitteilung | EQS Group News-Service |
576859 24.05.2017 CET/CEST
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|